Vicore Pharma Holding AB (6Y4) Stock Statistics & Valuation Metrics

Vicore Pharma Holding AB has a market cap or net worth of €198.41M. The enterprise value is ―.

Vicore Pharma Holding AB has 234,579,120 shares outstanding. The number of shares has decreased by -2.65% in one year.

Vicore Pharma Holding AB’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Vicore Pharma Holding AB is 0.00. Vicore Pharma Holding AB’s PEG ratio is -0.09.

In the last 12 months, Vicore Pharma Holding AB had revenue of 109.35M and earned -168.63M in profits. Earnings per share was -1.51.

In the last 12 months, operating cash flow was -164.95M and capital expenditures 49.56M, giving a free cash flow of -164.95M billion.

Vicore Pharma Holding AB pays an annual dividend of €0.294, resulting in a dividend yield of ―

Vicore Pharma Holding AB upcoming earnings date is Aug 22, 2025, TBA Not Confirmed.

Vicore Pharma Holding AB as a current ratio of 16.50, with Debt / Equity ratio of 0.00%

In the past 12 months, Vicore Pharma Holding AB has paid -256.00K in taxes.

Vicore Pharma Holding AB EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Vicore Pharma Holding AB has €1.16B in cash and marketable securities with kr0.00 in debt, giving a net cash position of -€1.16B billion.

Gross margin is 98.72%, with operating margin of -177.59%, and net profit margin of -154.22%.

The average price target for Vicore Pharma Holding AB is ―, which is 11.43% higher than the current price. The consensus rating is ―